60 Degrees Pharmaceuticals Unveils Name of Chronic Babesiosis Clinical Trial: B-FREE Chronic Babesiosis Study

WASHINGTON, Oct. 09, 2025 (GLOBE NEWSWIRE) --  60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (“60 Degrees Pharma” or the “Company”), a pharmaceutical company focused on developing new medicines for vector-borne disease, announced today the name of its chronic babesiosis trial is the B-FREE Chronic Babesiosis Study.

Read more at globenewswire.com